AP24534

[Guest guest]

Dear Group,

There is a new trial coming soon from Araid. AP24534 – a novel

multi-targeted kinase inhibitor – has been designed to treat drug-resistant

chronic myeloid leukemia (CML). This new drug will be in a drug-resistant CML

group, according to initial clinical trials – the major clinical challenge

facing physicians caring for such patients. Introduction of AP24534 into

clinical development, targeted for later this year, will yield further support

for the effectiveness of our proprietary drug-discovery technologies and our

focus on building a pipeline of internally discovered small-molecule oncology

product candidates. http://www.ariad.com/wt/page/chairman_view_july2007

This should be ready for trial by the end of the year. Hang in there, there's

another life preserver coming your way.

Blessings,

Lottie

[Guest guest]

LOTTIE, I ASKED DR. TALPAZ ABOUT THE DREADED T 3151 AND HE SAID THAT IS WHAT

XL228 IS FOR ALSO, I DIDN'T KNOW THAT. I THINK HE IS WAITING FOR THE ARIAD TRIAL

TO START AT U. OF MICH. BUT, LIKE SPRYCEL, IT WILL START AT A VERY LOW DOSE AND

WORK UP. I AM ON 7.2 IN THE XL228, AND LEN IS ON 3.6, SHE WILL GO TO MY DOSE IN

A FEW WEEKS. I MAY KNOW THURS. HOW I AM DOING, THEY DID A FISH LAST WEEK, I

DON'T KNOW HOW LONG THE RESULTS TAKE, BUT THEN THEY WILL COMPARE TO THE FIRST

ONE THEY DID, AND WE WILL KNOW. IF IT IS NOT DOING ANYTHING, I MAY ASK DR. T TO

LET ME GO ON TASIGNA, IT SEEMS TO BE DOING WELL FOR OTHERS, BUT I DON'T WANT TO

START AT 800, I WANT TO START AT 400, I AM A WOOS! I GO TO ANN ARBOR WED.

EVENING, AND WILL DO LABS AND THE INFUSION IN THE MORNING, AND COME BACK HOME.

WILL KEEP YOU ALL POSTED, HOPE I DON'T UP-CHUCK AGAIN!!!! BOBBY

Lottie Duthu <lotajam@...> wrote: Dear Group,

Last week I wrote Araid and asked for information on their new trial drug

AP24534. I said I would let you know when and if I heard from them. Well I have

had 2 emails from them already today and I am happy to report to your that you

can also contact them if you want to find out if there is a trial near you.

This is one of their email responses.

" I can tell you that MDACC is one of two centers that are currently open and

accepting patients. The trial is very early stage and is designed to assess

appropriate dosing. The trials designed to fully explore efficacy will come

later in the program. That said I would leave it to you and the physicians at

MDACC to determine if you may be a candidate for the program. "

If anyone is interested, write me and I will give you the name and email address

to contact them. This is a highly touted trial and is also used in treating the

dreaded mutation T315i.

Blessings and peace,

Lottie